Some 190,000 men in the U.S. with non-metastatic prostate cancer were receiving continuous androgen deprivation therapy (ADT) at the end of 2008.
Cheryl Guttman Krader
Results of a retrospective study provide evidence supporting the use of ultrasound as follow-up imaging to detect relapses in patients with germ cell tumors (GCT).
Patients being treated with oral anticancer drugs for metastatic renal cell carcinoma (mRCC) demonstrate almost full adherence to their medication regimen, data show.
Combining the results of the diagnostic and first-surveillance prostate biopsies provides useful information about the risk of progression in patients being managed by active surveillance.
Androgen deprivation therapy (ADT) prior to salvage cryoablation appears to improve post-treatment morbidity to some extent but does not affect biochemical-free survival.
PSA screening is on the rise and varies according to age, family history, race/ethnicity, and insurance status.
Repeat intradetrusor injections of onabotulinumtoxinA (Botox) are associated with sustained efficacy and no new safety signals.
Localized prostate cancer survival outcomes better with radical prostatectomy than radiation therapy in large study
Analyses of data from the Prostate Cancer Outcomes Study (PCOS) show that among men with localized prostate cancer, treatment by radical prostatectomy results in significantly better 15-year overall and disease-specific survival outcomes compared with external beam radiotherapy (EBRT).
Findings from a study of patients who underwent surgical mesh removal over a 6-year period will hopefully help surgeons with their management decisions and counseling efforts, UCLA researchers reported at the AUA annual meeting in Atlanta.
In treating nocturia related to urgency, flexible-dose fesoterodine (Toviaz) demonstrates statistical superiority to placebo in several areas, according to a study presented at the AUA annual meeting here.